Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: EVH stock price vs TECH: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at TECH's multiple
Needs TECH P/S.
Implied fair value · at EVH's multiple
Needs EVH P/S.
Price unavailable
Metric by metric
Where each company leads, and how wide the gap is.
Growth lag
Reported gross margin
Operating income + D&A
Lower is better
Not comparable
Lower leverage
Statements
Annual statements in reported currencies, with calculations and source evidence.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Trendline
Nine period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
USD market cap plus reported borrowing debt, less cash and equivalents. This EV proxy excludes investments, preferred stock and noncontrolling-interest adjustments.
Complete market value, debt and cash evidence is required for enterprise value.
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
Evolent Health, Inc. · implied price per share
Five annual free-cash-flow observations are required for the filing-backed baseline.
BIO-TECHNE Corp · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
Cigna Group
EVH vs CI
MOLINA HEALTHCARE, INC.
EVH vs MOH
Teladoc Health, Inc.
EVH vs TDOC
CLOVER HEALTH INVESTMENTS, CORP. /DE
EVH vs CLOV
UNITEDHEALTH GROUP INC
EVH vs UNH
THERMO FISHER SCIENTIFIC INC.
EVH vs TMO
DANAHER CORP /DE/
EVH vs DHR
AGILENT TECHNOLOGIES, INC.
EVH vs A
WATERS CORP /DE/
EVH vs WAT
ILLUMINA, INC.
EVH vs ILMN
BRUKER CORP
EVH vs BRKR
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.
If you believe EVH can restore growth and margins enough to justify a re-rating toward TECH-like revenue multiples, then a speculative long may make sense because the current P/S is only 0.3x; otherwise, the weak fundamentals and distress signals argue against relying on TECH-implied $152.81 valuation.
EVH trades at 0.3x P/S and 0.8x EV/Revenue versus TECH at 9.1x P/S and 9.3x EV/Revenue, implying a very large valuation gap. However, that gap is largely explained by EVH’s negative margins, shrinking revenue, and weaker quality scores rather than a clear mispricing.
Supporting Metrics
